Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma-Reference-Cited by-同舟云学术

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Published:2024-08 Issue:5 Volume:391 Page:393-407
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hungria Vania¹,Robak Pawel¹,Hus Marek¹,Zherebtsova Vera¹,Ward Christopher¹,Ho P. Joy¹,Ribas de Almeida Ana Carolina¹,Hajek Roman¹,Kim Kihyun¹,Grosicki Sebastian¹,Sia Hanlon¹,Bryant Adam¹,Pitombeira de Lacerda Marcelo¹^ORCID,Aparecida Martinez Gracia¹,Sureda Balarí Anna Maria¹,Sandhu Irwindeep¹,Cerchione Claudio¹^ORCID,Ganly Peter¹,Dimopoulos Meletios¹,Fu Chengcheng¹,Garg Mamta¹,Abdallah Al-Ola¹,Oriol Albert¹,Gatt Moshe E.¹,Cavo Michele¹,Rifkin Robert¹,Fujisaki Tomoaki¹,Mielnik Michał¹,Pirooz Nick¹^ORCID,McKeown Astrid¹,McNamara Simon¹,Zhou Xiangdong¹,Nichols Maureen¹,Lewis Eric¹,Rogers Rachel¹,Baig Hena¹,Eccersley Lydia¹,Roy-Ghanta Sumita¹,Opalinska Joanna¹,Mateos María-Victoria¹

Affiliation:

1. From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in...

Funder

GlaxoSmithKline

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2405090

Reference29 articles.

1. Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019

2. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

4. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

5. Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to rescue a DreaMM deferred …;Med;2024-09

2. Treatment of Early Relapse: Non-CAR T Cells;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma;New England Journal of Medicine;2024-08

4. A Belantamab Mafodotin Revival in Multiple Myeloma Therapy;New England Journal of Medicine;2024-08

5. BCMA-directed therapy for early relapsed and/or refractory multiple myeloma;Nature Reviews Clinical Oncology;2024-07-19